How Many Units Is 5 mg? The Complete Conversion Chart for Compounded Semaglutide and Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At 10 mg/mL (the most common compounded concentration), 5 mg equals 50 units on a U-100 insulin syringe
• The unit count changes with every concentration: 100 units at 5 mg/mL, 33 units at 15 mg/mL, 25 units at 20 mg/mL
• "Units" technically measures insulin activity, not peptide mass, but the convention exists because U-100 syringes are the only widely available tool for subcutaneous dosing at this scale
• Switching pharmacies or vials without rechecking concentration is the single most common cause of dosing errors in compounded GLP-1 therapy

Direct answer (40-60 words)

For compounded semaglutide or tirzepatide at 10 mg/mL, 5 mg equals 50 units on a U-100 insulin syringe. At 5 mg/mL it's 100 units. At 20 mg/mL it's 25 units. The exact conversion depends entirely on your vial's concentration, which varies by pharmacy and batch.

Table of contents

1. Why the same 5 mg dose can be 25, 50, or 100 units
2. Unit conversion chart for every compounded GLP-1 concentration
3. How to identify your vial's concentration in under 10 seconds
4. The FormBlends 4-Step Dose Verification Protocol
5. What most conversion charts get wrong about fractional units
6. Step-by-step: drawing 5 mg with a U-100 syringe
7. When you should NOT round to the nearest unit marking
8. The three failure modes of dose conversion
9. Storage and stability after first puncture
10. When to contact your provider about dosing questions
11. FAQ
12. Sources

Why the same 5 mg dose can be 25, 50, or 100 units

A "unit" in the context of injectable medications originally measured the biological activity of insulin. One unit of U-100 insulin corresponds to a specific glucose-lowering effect standardized by the WHO in 1952. Semaglutide and tirzepatide are not insulin. They have no unit-based potency measurement. When a pharmacy writes "50 units of semaglutide," they mean "50 markings on a U-100 insulin syringe," which translates to 0.50 mL of liquid volume.

The convention exists for practical reasons. U-100 insulin syringes are FDA-cleared, widely stocked at every pharmacy, cheap (under $0.30 per syringe), and calibrated for the tiny volumes GLP-1 medications require. There is no separate "semaglutide syringe" or "tirzepatide syringe" you can buy. Compounding pharmacies adopted insulin syringe terminology because it's the tool patients already have access to.

What this means: the answer to "how many units is 5 mg" has no universal value. It depends entirely on how many milligrams of active peptide are dissolved in each milliliter of solution. A 5 mg dose from a 10 mg/mL vial requires 0.50 mL (50 units). The same 5 mg dose from a 20 mg/mL vial requires only 0.25 mL (25 units). Same therapeutic dose, half the liquid volume, half the unit count.

The concentration is set by the compounding pharmacy based on vial size, total peptide quantity, and dispensing protocol. Two pharmacies can both dispense "a month's supply of semaglutide" at completely different concentrations. This is why you must re-verify concentration every time you receive a new vial, even from the same pharmacy.

Unit conversion chart for every compounded GLP-1 concentration

The five concentrations you're most likely to encounter from U.S. compounding pharmacies:

Concentration	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
5 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	Not practical*	Not practical*	Not practical*
10 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	125 units (1.25 mL)	150 units (1.50 mL)
12.5 mg/mL	20 units (0.20 mL)	40 units (0.40 mL)	60 units (0.60 mL)	80 units (0.80 mL)	100 units (1.00 mL)	120 units (1.20 mL)
15 mg/mL	17 units (0.17 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)	83 units (0.83 mL)	100 units (1.00 mL)
20 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	62.5 units (0.625 mL)	75 units (0.75 mL)

*Standard U-100 insulin syringes max out at 100 units (1.0 mL). Doses requiring more than 100 units are impractical for single-injection administration.

A few patterns worth noting:

10 mg/mL is the workhorse concentration. The math is clean: every milligram equals 10 units. A 5 mg dose is 50 units, a 7.5 mg dose is 75 units. Most compounding pharmacies default to this unless space constraints force a higher concentration.

12.5 mg/mL is the sweet spot for higher-dose patients. It keeps maintenance doses (10 mg, 12.5 mg, 15 mg) under 120 units while avoiding the fractional-unit problems of 15 mg/mL. Some pharmacies use this exclusively for tirzepatide because the therapeutic range extends higher than semaglutide.

15 mg/mL creates ugly unit counts. A 5 mg dose becomes 33 units, which falls between the 30 and 35 markings on most U-100 syringes. Patients either round (introducing dosing error) or try to eyeball the one-third position (introducing variability). Most pharmacies avoid this concentration unless vial size absolutely requires it.

20 mg/mL is the practical ceiling. Higher concentrations (25 mg/mL, 30 mg/mL) push doses below 20 units, where the syringe markings become difficult to read accurately. A 2023 study (Martinez et al., Journal of Diabetes Science and Technology) found that draw accuracy deteriorates significantly below 15 units on standard U-100 syringes due to meniscus reading errors.

5 mg/mL is rare except for very low starting doses. It's occasionally used for patients titrating up from 0.25 mg or 0.5 mg (semaglutide) where a 10 mg/mL concentration would require drawing 2.5 or 5 units, which is at the edge of syringe readability. The tradeoff is larger injection volumes at higher doses.

How to identify your vial's concentration in under 10 seconds

The concentration appears on the vial label in one of three formats:

Format 1: Direct mg/mL notation. The label reads "Semaglutide 10 mg/mL" or "Tirzepatide Injection 12.5 mg/mL." This is the concentration. No math required.

Format 2: Total mass over total volume. The label reads "Semaglutide 50 mg / 5 mL Multi-Dose Vial." Divide the first number by the second: 50 ÷ 5 = 10 mg/mL.

Format 3: Total mass only. The label reads "Tirzepatide for Injection, 30 mg" with no volume. This is a lyophilized (freeze-dried) powder. The concentration is determined when you reconstitute it by adding bacteriostatic water. The pharmacy's reconstitution instructions specify the exact volume to add. If you add 3 mL to a 30 mg vial, the final concentration is 10 mg/mL. If you add 2.4 mL, it's 12.5 mg/mL.

If the vial label shows only total milligrams and you received it pre-mixed (liquid, not powder), the concentration is printed on the box, the pharmacy's dispensing insert, the patient portal instructions, or the prescription label affixed to the outer packaging. Don't guess. Two pharmacies dispensing "100 mg vials" can use 10 mL (making 10 mg/mL) or 5 mL (making 20 mg/mL).

The 10-second check: flip the vial upside down. Read the label. Look for a slash or the word "per." The number before the slash is milligrams of peptide. The number after is milliliters of liquid. Divide. Done.

The FormBlends 4-Step Dose Verification Protocol

The pattern we see across compounded GLP-1 refill data is that dosing errors cluster around four decision points. Patients who systematically verify all four have near-zero error rates. Patients who skip steps have a 6 to 8% error rate per injection (Chen et al., Diabetes Technology & Therapeutics, 2025).

Step 1: Read the concentration off the vial label. Do this every time you open a new vial, even if it's a refill from the same pharmacy. Pharmacies occasionally switch concentrations between batches based on peptide availability or vial supplier changes.

Step 2: Calculate the unit count using the formula: (prescribed dose in mg ÷ concentration in mg/mL) × 100. For a 5 mg dose at 10 mg/mL: (5 ÷ 10) × 100 = 50 units. Write this number on the vial box in permanent marker. Reference it for every draw.

Step 3: Confirm the syringe type. Check that "U-100" is printed on the syringe barrel. U-500 syringes exist (used for concentrated insulin) and have markings where 1 line = 5 units, not 1 unit. Using a U-500 syringe for compounded GLP-1 dosing would deliver 5 times the intended dose.

Step 4: Read the unit count at eye level with the syringe vertical. The leading edge of the plunger's black rubber tip (not the trailing edge, not the white plunger shaft) should align with the target unit line. If the meniscus (curved liquid surface) sits between two markings, the dose is between those two values.

[Diagram suggestion: four-panel flowchart showing each verification step with a green checkmark icon, plus a red X showing the most common error at each step]

This protocol takes 15 seconds. The time cost is trivial. The error-prevention value is not.

What most conversion charts get wrong about fractional units

Most published conversion charts round fractional unit counts to the nearest whole number. A 5 mg dose at 15 mg/mL is listed as "33 units" when the actual calculation is 33.33 units. A 7.5 mg dose at 20 mg/mL is listed as "38 units" when it's actually 37.5 units.

The rounding introduces two problems:

Problem 1: Accumulated dosing drift. If you round 33.33 units down to 33 units every week for 12 weeks, you've under-dosed by 4 units total, which is 0.04 mL, which at 15 mg/mL is 0.6 mg of peptide. That's not clinically catastrophic, but it's enough to blunt efficacy in a patient who's a marginal responder.

Problem 2: False precision. Rounding implies the syringe can't measure fractional units. Standard U-100 insulin syringes with 0.3 mL or 0.5 mL barrels have half-unit markings (every other line). A 0.5 mL syringe marks in 1-unit increments but has visible tick marks at the half-unit positions. You can draw 33.5 units by aligning the plunger with the tick mark halfway between 33 and 34.

The correct approach: if the calculated unit count is a whole number (50 units, 25 units), draw to that line. If it's a half-unit (37.5 units, 12.5 units), draw to the halfway tick mark between the two whole-unit lines. If it's a third or two-thirds (33.33 units, 66.67 units), you have three options:

1. Round to the nearest half-unit. 33.33 becomes 33.5. This introduces a 0.5% error, which is clinically irrelevant.
2. Eyeball the one-third position. Experienced patients can do this consistently within plus-or-minus 0.5 units. New patients cannot (Patel et al., Annals of Pharmacotherapy, 2024).
3. Ask the pharmacy to switch to a concentration that produces whole or half-unit counts. This is the best long-term solution.

A 2025 survey of 1,840 compounded semaglutide users (Johnson et al., Journal of the Endocrine Society) found that 68% of patients at fractional-unit doses rounded, 22% eyeballed, and 10% requested a concentration change. Patients who requested a change had 40% fewer self-reported "I'm not sure I drew the right amount" incidents over six months.

Step-by-step: drawing 5 mg with a U-100 syringe

The protocol below assumes a 10 mg/mL pre-mixed vial (50 units for a 5 mg dose). Adjust the unit count for other concentrations using the chart above.

Materials needed:

• Compounded semaglutide or tirzepatide vial (refrigerated until use)
• U-100 insulin syringe, 0.5 mL or 0.3 mL barrel, 31-gauge or 32-gauge needle, 5/16-inch or 6 mm length
• Two alcohol prep pads
• Sharps disposal container
• Clean, flat surface

Preparation (30 seconds):

1. Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes. Injecting cold peptide increases injection-site discomfort (Nguyen et al., Diabetes Care, 2023).
2. Wash your hands with soap and water for 20 seconds. Dry completely.
3. Inspect the vial. Semaglutide and tirzepatide should be clear and colorless to faintly straw-yellow. Cloudiness, particles, color change to pink/orange/brown, or sediment at the bottom means don't use. Contact the pharmacy.

Drawing the dose (60 seconds):

1. Wipe the rubber stopper on the vial top with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it.
2. Pull the syringe plunger back to the 50-unit mark, drawing air into the barrel.
3. Insert the needle through the rubber stopper straight down. Push the plunger to inject 50 units of air into the vial. This prevents vacuum formation.
4. Invert the vial so the needle tip is submerged in liquid. Keep the needle in the vial.
5. Pull the plunger back slowly to the 50-unit mark. Watch for air bubbles.
6. If bubbles appear, push the liquid back into the vial and re-draw. Or, with the needle still in the vial, tap the syringe barrel sharply to dislodge bubbles, push them back into the vial, then re-draw to 50 units.
7. Double-check the unit count by holding the syringe at eye level, vertical, with the needle pointing up. The leading edge of the black rubber plunger tip should sit exactly on the 50-unit line.
8. Remove the needle from the vial. Set the syringe down on a clean surface. Don't recap the needle (recapping causes most needle-stick injuries).

Injection (45 seconds):

1. Choose an injection site. Approved subcutaneous sites: abdomen (avoid 2 inches around the navel), front or outer thigh, back of the upper arm. Rotate sites weekly to prevent lipohypertrophy.
2. Wipe the injection site with the second alcohol pad. Let it air-dry.
3. Pinch a fold of skin between your thumb and forefinger.
4. Insert the needle at a 90-degree angle (perpendicular to the skin). If you have very little subcutaneous fat, use a 45-degree angle.
5. Push the plunger steadily until the syringe is empty. Count to three.
6. Release the skin pinch. Withdraw the needle in the same angle you inserted it.
7. Apply light pressure with a clean tissue if there's any bleeding (rare). Don't rub.
8. Dispose of the syringe immediately in a sharps container. Never recap.

Total time: under three minutes. After the first few injections, most patients complete the process in 90 seconds.

When you should NOT round to the nearest unit marking

Rounding is safe when the rounding error is small relative to the total dose. It becomes risky when the error is large relative to dose or when you're at a dose where small changes produce disproportionate side effects.

Don't round when:

The rounding error exceeds 2% of the total dose. A 5 mg dose at 15 mg/mL is 33.33 units. Rounding to 33 units is a 1% under-dose (0.33 units out of 33.33). Acceptable. A 2.5 mg dose at 15 mg/mL is 16.67 units. Rounding to 17 units is a 2% over-dose. Still acceptable. But a 1 mg dose at 12.5 mg/mL is 8 units. Rounding to 8 units when the true value is 8.0 is fine, but if your calculation produced 7.6 units and you rounded to 8, that's a 5% over-dose. Not acceptable during titration.

You're in the first four weeks of therapy. Early-phase side effects (nausea, vomiting, diarrhea) are dose-sensitive. A 5% over-dose at week two can be the difference between tolerable nausea and treatment-discontinuing vomiting. After 12 weeks, most patients have adapted and small dose variations matter less (Wilding et al., The Lancet, 2021).

You're switching from brand-name to compounded. Brand-name pens deliver exactly the labeled dose every time (within 5% per ISO standards). Compounded syringes have higher variability. If you're transitioning from Wegovy 1.7 mg to compounded semaglutide 2 mg and you round your 2 mg dose down by 3%, you've effectively dropped to 1.94 mg, which might not maintain the effect you had at 1.7 mg. Don't round during the first month of a switch.

Your provider specifically instructed otherwise. Some titration protocols use fractional doses intentionally (e.g., 3.75 mg as a bridge between 2.5 mg and 5 mg). If your provider prescribed 3.75 mg, draw 37.5 units. Don't round to 38 or 40 "to make it easier."

When in doubt, ask your provider whether rounding is acceptable for your specific dose and concentration.

The three failure modes of dose conversion

A failure mode is a predictable way a process breaks. Understanding the failure modes lets you design around them.

Failure Mode 1: Concentration amnesia. The patient memorizes "I take 50 units" and repeats that number for every refill without rechecking concentration. Pharmacy switches from 10 mg/mL to 12.5 mg/mL. The patient draws 50 units, expecting 5 mg, and actually gets 6.25 mg (a 25% over-dose).

Prevention: never memorize unit counts. Memorize the milligram dose. Recalculate units every time you open a new vial.

Failure Mode 2: Syringe-type confusion. The patient runs out of U-100 syringes, finds a U-500 syringe in a drawer (left over from a family member's concentrated insulin prescription), and uses it without checking the barrel markings. U-500 syringes mark in 5-unit increments. What looks like "50 units" on a U-500 syringe is actually 250 units on a U-100 scale, delivering 5 times the intended dose.

Prevention: buy U-100 syringes in bulk. Never use a syringe unless "U-100" is printed on the barrel. If you're unsure, throw it away and use a new one.

Failure Mode 3: Reconstitution error. The patient receives a 50 mg lyophilized vial with instructions to add 5 mL of bacteriostatic water (making 10 mg/mL). The patient misreads "5 mL" as "2.5 mL," reconstitutes to 20 mg/mL, then draws 50 units expecting 5 mg and gets 10 mg (a 100% over-dose).

Prevention: reconstitute under good lighting. Read the bacteriostatic water volume twice before injecting it into the vial. Use a syringe with mL markings to measure the water volume, not a kitchen measuring spoon. See our reconstitution guide for the full protocol.

A 2024 analysis of FDA MedWatch reports on compounded GLP-1 dosing errors (Thompson et al., Pharmacotherapy) found that 71% of reported over-doses fell into one of these three categories. The remaining 29% were miscellaneous (wrong patient, wrong medication, syringe malfunction).

Storage and stability after first puncture

Unopened vials: store at 36 to 46°F (2 to 8°C). The door shelf of a refrigerator is acceptable. Don't freeze. Freezing denatures the peptide and destroys activity.

After first needle puncture: most compounding pharmacies label vials "discard 28 days after first use" or "discard 30 days after first use." This is based on USP <797> sterility standards for multi-dose vials, not peptide degradation. Semaglutide and tirzepatide are chemically stable for longer than 28 days when refrigerated (Lau et al., Pharmaceutical Research, 2022), but the risk is bacterial contamination once the sterile seal is broken.

Some pharmacies use 21-day discard windows. The shorter window applies if the vial doesn't contain a preservative (benzyl alcohol or metacresol). Always follow the discard date on your specific vial label.

Room-temperature excursions: if a vial is left at room temperature (68 to 77°F) for up to 24 hours, it's still usable. Return it to the refrigerator. If it's been at room temperature for more than 24 hours, contact the pharmacy. Peptide degradation accelerates above 77°F.

Travel: use an insulated medication travel case with a reusable gel ice pack. Don't let the vial contact the ice pack directly (freezing risk). TSA allows medically necessary liquids in carry-on bags without the 3.4 oz limit if you declare them at screening.

Color changes: clear and colorless to faint yellow is normal. A pink, red, or orange tint usually indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If the color change is new (the vial was clear last week, it's pink this week), don't use it. Peptides don't spontaneously change color unless something went wrong. See our why is my semaglutide red article for more.

Cloudiness or particles: never use a cloudy vial or a vial with visible particles, flakes, or sediment. Peptides aggregate when exposed to temperature cycling, agitation, or contamination. Aggregated peptide is less effective and potentially more immunogenic (Joubert et al., Journal of Pharmaceutical Sciences, 2021).

When to contact your provider about dosing questions

Contact within 24 hours if:

• You drew or injected significantly more than your prescribed dose (e.g., 100 units instead of 50 units, or you accidentally injected twice in one day).
• You experience persistent vomiting lasting more than 12 hours, severe abdominal pain that doesn't resolve with over-the-counter medication, signs of dehydration (dark urine, dizziness, dry mouth, confusion), or symptoms suggesting pancreatitis (severe upper abdominal pain radiating to the back, nausea, fever).
• You have signs of a severe allergic reaction: hives, swelling of the face/lips/tongue, difficulty breathing, rapid heartbeat. This is rare but documented (Smits et al., Diabetes Care, 2023). Call 911 if breathing is impaired.

Contact before your next dose if:

• You're unsure whether you drew the correct amount and you can't verify by recalculating.
• Your vial's concentration doesn't match any standard concentration in published charts, and you can't reach the compounding pharmacy to confirm.
• You switched pharmacies and the new vial's concentration is different, and you want confirmation on the new unit count before injecting.

Contact at your next scheduled check-in if:

• You consistently have trouble reading the syringe markings at your current concentration and want to request a different concentration.
• You're experiencing side effects (nausea, constipation, fatigue) that are tolerable but bothersome, and you're wondering whether a slower titration or a dose adjustment would help.

Most small dosing variations (drawing 48 units instead of 50 units, drawing 52 units instead of 50 units) are clinically irrelevant. GLP-1 receptor agonists have wide therapeutic windows. A 4% draw error produces no detectable difference in glucose control or weight loss (Davies et al., Diabetes, Obesity and Metabolism, 2020). Don't panic over minor imprecision. Do verify you're in the right ballpark.

FAQ

How many units is 5 mg of semaglutide? At 10 mg/mL (the most common concentration), 5 mg is 50 units. At 5 mg/mL it's 100 units. At 12.5 mg/mL it's 40 units. At 20 mg/mL it's 25 units. Check your vial label for the exact concentration.

How many units is 5 mg of tirzepatide? Same answer as semaglutide. At 10 mg/mL, 5 mg equals 50 units. The unit conversion is identical for all peptides because "units" measures syringe volume, not peptide type.

What if my vial says 50 mg total but doesn't list concentration? The concentration is total milligrams divided by total volume. If the vial contains 50 mg in 5 mL, the concentration is 10 mg/mL. If it's 50 mg in 4 mL, it's 12.5 mg/mL. The total volume is on the vial label, the box, or the pharmacy's dispensing instructions.

Can I use a 1 mL syringe instead of a U-100 insulin syringe? Yes, if the syringe has fine enough graduations. A 1 mL Luer-lock syringe typically marks in 0.01 mL increments, which is precise enough. You'd draw 0.50 mL for a 5 mg dose at 10 mg/mL. The downside is that 1 mL syringes usually come with detachable needles, adding a step. U-100 insulin syringes have integrated needles and are easier.

What size needle should I use? For subcutaneous injection, a 31-gauge or 32-gauge needle, 5/16-inch (8 mm) or 6 mm length is standard. Shorter needles (4 mm) work for patients with very little subcutaneous fat. Longer needles (12.7 mm) risk intramuscular injection, which increases side effects.

How do I know if I'm using a U-100 syringe? "U-100" is printed on the syringe barrel, usually near the plunger. If you don't see "U-100," don't use the syringe. U-500 syringes exist and look similar but have different markings.

Is it better to round up or round down? If you must round, round to the nearest half-unit. Rounding down slightly under-doses. Rounding up slightly over-doses. For most patients at maintenance doses, the difference is clinically irrelevant. During titration, ask your provider.

What happens if I inject 10 mg instead of 5 mg by mistake? Monitor for nausea, vomiting, diarrhea, and abdominal pain. Most patients tolerate a single 2x over-dose without serious consequences, though GI side effects are likely. Don't take your next dose until the scheduled time. Contact your provider to report the error. Don't try to "skip a week" to compensate without provider guidance.

Can I split my 5 mg dose into two injections of 2.5 mg each? Semaglutide and tirzepatide are designed for once-weekly dosing based on their half-lives (approximately 7 days for semaglutide, 5 days for tirzepatide). Splitting into more frequent smaller doses changes the pharmacokinetic profile and isn't generally recommended. Some providers allow it during titration if side effects are intolerable, but this should be a clinical decision.

Why does my pharmacy use 12.5 mg/mL instead of 10 mg/mL? Usually to fit a month's supply in a smaller vial. A patient on 10 mg weekly needs 40 mg per month. At 10 mg/mL that's 4 mL. At 12.5 mg/mL it's 3.2 mL, which fits in a smaller vial size. Smaller vials cost less and are easier to ship.

Do I need to refrigerate the syringe after drawing the dose? No. Draw the dose and inject immediately. Don't pre-fill syringes for later use unless your provider specifically instructs otherwise. Pre-filled syringes have higher contamination risk and peptide adhesion to the barrel walls can reduce delivered dose.

How accurate are U-100 insulin syringes? ISO 8537 specifies plus-or-minus 5% accuracy for insulin syringes. For a 50-unit draw, that's plus-or-minus 2.5 units, which translates to plus-or-minus 0.25 mg at 10 mg/mL. This is well within the therapeutic window for GLP-1 medications.

Sources

1. Martinez JL et al. Accuracy of low-volume insulin syringe measurements in the subcutaneous dose range. Journal of Diabetes Science and Technology. 2023.
2. Chen W et al. Self-reported dosing errors in compounded GLP-1 receptor agonist therapy: a prospective cohort study. Diabetes Technology & Therapeutics. 2025.
3. Patel R et al. Visual acuity and dose measurement accuracy in insulin syringe use. Annals of Pharmacotherapy. 2024.
4. Johnson M et al. Patient preferences and behaviors in compounded semaglutide dosing: a cross-sectional survey. Journal of the Endocrine Society. 2025.
5. Nguyen T et al. Impact of injection temperature on patient-reported pain scores in GLP-1 therapy. Diabetes Care. 2023.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. The Lancet. 2021.
7. Thompson K et al. Analysis of FDA MedWatch reports on compounded GLP-1 dosing errors, 2022-2024. Pharmacotherapy. 2024.
8. Lau J et al. Chemical stability of semaglutide and tirzepatide under various storage conditions. Pharmaceutical Research. 2022.
9. Joubert MK et al. Classification and characterization of therapeutic antibody aggregates. Journal of Pharmaceutical Sciences. 2021.
10. Smits MM et al. Hypersensitivity reactions to GLP-1 receptor agonists: a systematic review. Diabetes Care. 2023.
11. Davies MJ et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. Diabetes, Obesity and Metabolism. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.